Quick answers
- What is Ticagrelor used for?
- The FDA-approved label (Brilinta, AstraZeneca Pharmaceuticals LP, May 7, 2026) says: “BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ticagrelor have a boxed warning?
- Yes. The FDA label for Brilinta has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Ticagrelor?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Ticagrelor been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Ticagrelor?
- 30 companies list prescription products of Ticagrelor in the FDA NDC Directory, including Aphena Pharma Solutions - Tennessee, LLC, Oryza Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc..
What Ticagrelor is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. …
— FDA label: Brilinta, AstraZeneca Pharmaceuticals LP, effective May 7, 2026. Read the full label on DailyMed →
The FDA has 32 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
32 of 32 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 56 in the FDA NDC Directory |
| Brand names | Brilinta |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ticagrelor 60 mg tablet | Generic | $0.2624 per tablet |
| ticagrelor 60 mg tablet | Brand: Brilinta | $7.42 per tablet |
| ticagrelor 60 mg tablet, film coated | Generic | $0.2624 per tablet |
| ticagrelor 90 mg tablet | Generic | $0.2429 per tablet |
| ticagrelor 90 mg tablet | Brand: Brilinta | $7.42 per tablet |
| ticagrelor 90 mg tablet, film coated | Generic | $0.2429 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Aphena Pharma Solutions - Tennessee, LLC4 products
- Oryza Pharmaceuticals Inc.2 products
- Exelan Pharmaceuticals Inc.2 products
- Macleods Pharmaceuticals Limited2 products
- AstraZeneca Pharmaceuticals LP2 products
- Apotex Corp.2 products
- Lifestar Pharma LLC2 products
- Dr.Reddys Laboratories Inc2 products
- Alembic Pharmaceuticals Limited2 products
- Alembic Pharmaceuticals Inc.2 products
- Cipla USA Inc.2 products
- Novadoz Pharmaceuticals LLC2 products
- NorthStar RxLLC2 products
- AvKARE2 products
- Radha Pharmaceuticals, Inc.2 products
- AiPing Pharmaceutical, Inc.2 products
- American Health Packaging2 products
- Ascend Laboratories, LLC2 products
- Laurus Labs Limited2 products
- Changzhou Pharmaceutical Factory2 products
- Bionpharma Inc.2 products
- Teva Pharmaceuticals, Inc.2 products
- ScieGen Pharmaceuticals, Inc.2 products
- Mylan Pharmaceuticals Inc.2 products
- Cardinal Health 107, LLC1 product
- Golden State Medical Supply, Inc.1 product
- Solco Healthcare U.S., LLC1 product
- Redpharm Drug1 product
- Hisun Pharmaceuticals USA, Inc.1 product
- AvPAK1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022433 BRILINTA | Astrazeneca | July 20, 2011 | 28, latest May 7, 2026 2026: Labeling · 2024: Labeling · 2024: Efficacy |
Generic approvals (18)
- ANDA208390Watson Labs Inc · September 4, 2018
- ANDA208575Hisun Pharm Hangzhou · January 23, 2019
- ANDA208508Sunshine · April 6, 2020
- ANDA208596Msn · April 7, 2020
- ANDA208597Mylan · July 9, 2021
- ANDA208567Alkem Labs Ltd · April 21, 2023
- ANDA208599Prinston Inc · August 16, 2024
- ANDA208541DR Reddys · October 29, 2024
- ANDA208584Apotex · May 1, 2025
- ANDA208576Alembic · May 2, 2025
- ANDA208537Invagen Pharms · May 5, 2025
- ANDA210219Alkem Labs Ltd · October 28, 2025
- ANDA212258Macleods Pharms · October 28, 2025
- ANDA216187Changzhou Pharm · October 28, 2025
- ANDA218962Sciegen Pharms · October 28, 2025
- ANDA217679Mankind Pharma · February 6, 2026
- ANDA219006Zhejiang Jingxin · March 24, 2026
- ANDA218869Pharmobedient · August 20, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0433-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Brilinta ticagrelar tablets 60 mg 60 tablets Rx only NDC 0186-0776-60 Mfd. for: AstraZeneca LP, Wilmington, DE 19850 — Cardinal Health Inc.
-
May 25, 2017 · Class I · Terminated · D-0958-2017
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08. — AstraZeneca Pharmaceuticals, LP
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1116635, 1116639, 1666332, 1666334 |
|---|---|
| SPL set ID of the quoted label | f7b3f443-e83d-4bf2-0e96-023448fed9a8 |
| FDA labels (SPL) | 32 |
| FDA applications | NDA022433, 18 ANDA |
| Active ingredients (FDA) | TICAGRELOR |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Brilinta, AstraZeneca Pharmaceuticals LP, effective May 7, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →